Autoimmune hepatitis: Current and future therapies

Area of Science:

• Hepatology
• Immunology
• Autoimmune Diseases

Background:

• Autoimmune hepatitis (AIH) is a chronic, heterogeneous liver disease predominantly affecting women, potentially leading to cirrhosis and liver failure.
• Current standard treatments involve immunosuppressants, but long-term use carries significant adverse effects.
• The complex pathogenesis of AIH involves immune cell infiltration and inflammatory cascades, yet targeted therapies remain limited.

Purpose of the Study:

• To highlight the challenges in advancing AIH treatment paradigms.
• To emphasize the need for improved clinical trial designs and outcome assessments.
• To advocate for individualized and steroid-free treatment strategies.

Main Methods:

• Review of current understanding of AIH pathogenesis and treatment limitations.
• Analysis of obstacles in clinical trial conduct, including patient recruitment and diversity.
• Discussion of the need for defined outcomes and adaptive study designs.

Main Results:

• Progress in AIH treatment has lagged behind other autoimmune diseases.
• Clinical trials face significant hurdles, including patient diversity and outcome measurement.
• Current treatment strategies lack personalization and contribute to steroid-related side effects.

Conclusions:

• Individualized and steroid-free treatment approaches are essential for improving AIH prognosis.
• Addressing challenges in clinical trials is critical for developing novel therapies.
• Minimizing steroid-associated adverse effects is a key goal for enhancing patient quality of life.